<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02958865</url>
  </required_header>
  <id_info>
    <org_study_id>B7981005</org_study_id>
    <secondary_id>VIBRATO</secondary_id>
    <secondary_id>2016-003708-29</secondary_id>
    <nct_id>NCT02958865</nct_id>
  </id_info>
  <brief_title>Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis</brief_title>
  <official_title>A Phase 2b, Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Ranging Study Of Oral Pf-06651600 And Pf 06700841 As Induction And Chronic Therapy In Subjects With Moderate To Severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective
      in treatment of moderate to severe ulcerative colitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2017</start_date>
  <completion_date type="Anticipated">January 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Total Mayo Score</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving remission based on total Mayo score</measure>
    <time_frame>Week 8</time_frame>
    <description>Remission excludes friability and is based on total Mayo score of less than/equal to 2 with no individual subscore greater than 1 at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in remission based on total Mayo score</measure>
    <time_frame>Week 32</time_frame>
    <description>Remission excludes friability and is based on total Mayo score of less than/equal to 2 with no individual subscore greater than 1 at week 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving improvement in endoscopic appearance</measure>
    <time_frame>Week 8</time_frame>
    <description>Improvement of endoscopic appearance is defined as a Mayo endoscopic subscore of less than/equal to 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving clinical response</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical response is defined as a decrease from baseline in total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in endoscopic remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Endoscopic remission is defined as an endoscopic subscore of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in symptomatic remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Symptomatic remission is defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and both rectal bleeding and stool frequency subscores of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving deep remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Deep remission is defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a 0 on both endoscopic and rectal bleeding subscores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Mayo Scores and changes from baseline</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 24, and 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total Mayo score</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total Mayo score</measure>
    <time_frame>Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores and changes from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score and domains</measure>
    <time_frame>Weeks 4, 8, and 32</time_frame>
    <description>IBDQ domains include Bowel Symptoms, Systemic Symptoms, Emotional Function and Social Function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with IBDQ total score greater than/equal to 170.</measure>
    <time_frame>Weeks 4, 8, and 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with greater than/equal to 16 point increase in IBDQ total score from baseline</measure>
    <time_frame>Weeks 4, 8, and 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with improvement in IBDQ bowel symptom domain</measure>
    <time_frame>Weeks 4, 8, and 32</time_frame>
    <description>Improvement is defined as an increase of at least 1.2 points from baseline in average score among IBDQ bowel symptom domain (items 1, 5, 9, 13, 17, 20, 22, 24, 26, 29).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores and changes from baseline in SF-36 v2</measure>
    <time_frame>Weeks 4, 8, and 32</time_frame>
    <description>SF-36 physical and mental component summary scores: PCS and MCS, and 8 domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores and changes from baseline in EuroQoL-5 Dimensions</measure>
    <time_frame>Weeks 4, 8, and 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious infections</measure>
    <time_frame>Baseline through week 36</time_frame>
    <description>Serious infections are treated infections that require parenteral antimicrobial therapy and present with positive pre-treatment culture AND EITHER require hospitalization for treatment OR meet other criteria that require the infection to be classified as an SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving improvement in endoscopic appearance</measure>
    <time_frame>Week 32</time_frame>
    <description>Improvement of endoscopic appearance is defined as a Mayo endoscopic subscore of less than/equal to 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving clinical response</measure>
    <time_frame>Week 32</time_frame>
    <description>Clinical response is defined as a decrease from baseline in total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in endoscopic remission</measure>
    <time_frame>Week 32</time_frame>
    <description>Endoscopic remission is defined as an endoscopic subscore of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in symptomatic remission</measure>
    <time_frame>Week 32</time_frame>
    <description>Symptomatic remission is defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and both rectal bleeding and stool frequency subscores of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving deep remission</measure>
    <time_frame>Week 32</time_frame>
    <description>Deep remission is defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a 0 on both endoscopic and rectal bleeding subscores.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>PF-06651600 Drug Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivered orally for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06651600 Drug Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivered orally for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06651600 Drug Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivered orally for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06651600 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Delivered orally for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 Drug Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivered orally for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 Drug Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivered orally for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 Drug Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivered orally for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Delivered orally for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06651600 Drug Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivered orally for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 Drug Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivered orally for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06651600 Placebo 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Delivered orally for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 Placebo 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Delivered orally for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06651600 or Placebo</intervention_name>
    <description>Delivered orally for 8 weeks.</description>
    <arm_group_label>PF-06651600 Drug Dose Level 1</arm_group_label>
    <arm_group_label>PF-06651600 Drug Dose Level 2</arm_group_label>
    <arm_group_label>PF-06651600 Drug Dose Level 3</arm_group_label>
    <arm_group_label>PF-06651600 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06700841 or Placebo</intervention_name>
    <description>Delivered orally for 8 weeks.</description>
    <arm_group_label>PF-06700841 Drug Dose Level 1</arm_group_label>
    <arm_group_label>PF-06700841 Drug Dose Level 2</arm_group_label>
    <arm_group_label>PF-06700841 Drug Dose Level 3</arm_group_label>
    <arm_group_label>PF-06700841 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06700841 or Placebo</intervention_name>
    <description>Delivered orally for 24 weeks.</description>
    <arm_group_label>PF-06700841 Drug Dose Level 4</arm_group_label>
    <arm_group_label>PF-06700841 Placebo 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06651600 or Placebo</intervention_name>
    <description>Delivered orally for 24 weeks.</description>
    <arm_group_label>PF-06651600 Drug Dose Level 4</arm_group_label>
    <arm_group_label>PF-06651600 Placebo 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ulcerative colitis for greater than/equal to 4 months.

          -  Moderate to severe active ulcerative colitis

          -  Inadequate response to, loss of response to, or intolerance to at least one
             conventional therapy for UC.

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Clinical findings suggestive of Crohn's Disease

          -  History of bowel surgery within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>San Diego Endoscopy Center (Endoscopies Only)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Hospital</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Foundation</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Connecticut Endoscopy Center</name>
      <address>
        <city>Plainville</city>
        <state>Connecticut</state>
        <zip>06062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GastroIntestinal Specialists, A.M.C.</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shreveport Endoscopy Center, A.M.C.</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chevy Chase Endoscopy Center</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MGG Group Co. Inc., Chevy Chase Clinical Research</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology Research, LLC</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Endoscopy Center of Lake County</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7981005&amp;StudyName=A+Phase+2b%2C+Double-blind%2C+Randomized%2C+Placebo-controlled+%2C+Parallel+Group%2C+Dose+Ranging+Study+Of+Oral+Pf-06651600+And+Pf-06700841+As+Induction+And+Chronic+Therapy+In+Subjects+With+Moderate+To+Severe+Ulcerative+Colitis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7981005&amp;StudyName=A+Phase+2b%2C+Double-blind%2C+Randomized%2C+Placebo-controlled%2C+Parallel+Group%2C+Dose+Ranging+Study+Of+Oral+Pf-06651600+And+Pf+06700841+As+Induction+And+Chronic+Therapy+In+Subjects+With+Moderate+To+Severe+Ulcerative+Colitis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>November 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mayo score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
